Overcoming the toxicity hurdles of genetically targeted T cells

Area of Science:

• Immunology
• Gene Therapy
• Oncology

Background:

• Clinical trials using genetically modified T cells (TCR and CAR T cells) have shown significant success.
• These advanced therapies also present notable toxicities that require careful management.

Purpose of the Study:

• To review and describe adverse events observed in clinical trials involving genetically modified T cells.
• To correlate these toxicities with the underlying biology of engineered T cells.
• To propose and discuss strategies for mitigating these adverse events.

Main Methods:

• Focused literature review of clinical trials involving genetically modified T cells.
• Analysis of reported adverse events and their biological basis.
• Exploration of potential safety strategies, including suicide gene therapy.

Main Results:

• Genetically modified T cell therapies are associated with a range of adverse events.
• Understanding the complex biology of engineered T cells is crucial for predicting and managing toxicities.
• Various strategies, such as suicide gene systems, offer potential solutions for enhancing safety.

Conclusions:

• While T cell therapies are powerful, their toxicities necessitate proactive management.
• Innovative gene therapy approaches, including suicide genes, are vital for improving the safety profile of these treatments.
• Further research into mitigating adverse events will accelerate the clinical application of T cell-based immunotherapies.